Pathological laughter following intravenous sodium valproate

Canadian Journal of Neurological Sciences

Volumn 25, Issue 3, 1998, Pages 252-253

  Jacob, P C ^a   Chand, R Pratap ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; VALPROIC ACID;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CASE REPORT; DRUG INDUCED DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; NONVERBAL COMMUNICATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

EID: 0031823064     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100034107     Document Type: Article

References (6)

1. Devinsky O, Leppik I, Wilmore LJ, et al. Intravenous Valproate Study Team. Safety of intravenous valproate. Ann Neurol 1995; 38: 670-674.
2. Black DW. Pathological laughter: a review of the literature. J Nerv Mem Dis 1982; 170: 67-71.
3. Zellers GL, Frank M, Daugherly J. Pathological laughter. Ann Emerg Med 1990; 19: 327-329.
4. Gascon GG, Lombroso CT. Epileptic (gelastic) laughter. Epilepsia 1971; 12: 63-76.
5. Breningstall GN. Gelastic seizures, precocious puberty and hypothalamic hamartoma. Neurology 1985; 35: 1180-1183.
6. Saitoh S, Nickawa N. The GABA A receptor beta 3 subunit gene (GABRB 3) as a candidate responsible for the central nervous disturbances in Angelman syndrome (AS). Nippon-Rinsho 1993; 51: 2409-24113.